Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BIOCRYST PHARMACEUTICALS, INC.

(BCRX)
  Rapport
Vertraagde tijd Nasdaq  -  22:00 06-10-2022
14.20 USD   +0.42%
14/09BioCryst Pharmaceuticals benoemt Chief Medical Officer
MT
14/09BioCryst Pharmaceuticals, Inc. Benoemt Dr. Bill Sheridan tot Chief Development Officer en benoemt Dr. Ryan Arnold tot Chief Medical Officer
CI
31/08BioCryst Pharmaceuticals ontvangt aanwijzing als weesgeneesmiddel voor behandeling van botaandoening
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciënConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiële publicatiesSectornieuws
Communiqués de presse de la société BIOCRYST PHARMACEUTICALS, INC.
05/10BioCryst Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
04/10BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
04/10Yellow Fever Pipeline Landscape Analysis of 10+ Companies by DelveInsight | Leading Com..
AQ
15/09Parexel Appoints Peyton Howell Chief Operating and Growth Officer; Promotes FDA Veteran..
AQ
14/09Biocryst Pharmaceuticals Inc : Change in Directors or Principal Officers, Regulation FD Di..
AQ
14/09BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold..
AQ
06/09BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
31/08BioCryst to Present at Upcoming Investor Conferences
AQ
31/08FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Tre..
AQ
29/08BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Com..
AQ
26/08BioCryst Pharmaceuticals, Inc. - U.S. Government Exercises Option to Purchase Additiona..
AQ
26/08BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Com..
AQ
25/08Biocryst Pharmaceuticals Inc : Regulation FD Disclosure, Other Events, Financial Statement..
AQ
25/08U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) ..
AQ
18/08BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia
AQ
05/08BIOCRYST PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Conditi..
AQ
04/08Biocryst Pharmaceuticals : Second Quarter 2022 Conference Call
PU
04/08Biocryst : Q2 Earnings Snapshot
AQ
04/08Biocryst Pharmaceuticals : Reports Second Quarter 2022 Financial Results and Upcoming Key ..
PU
04/08Biocryst Pharmaceuticals Inc : Results of Operations and Financial Condition, Regulation F..
AQ
04/08BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones
AQ
04/08BioCryst Resumes Enrollment in BCX9930 Clinical Program
AQ
21/07BioCryst to Report Second Quarter 2022 Financial Results on August 4
AQ
18/07BioCryst to Present at Upcoming Investor Conference
AQ
15/07BioCryst to Present at Upcoming Investor Conference
AQ
04/07BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patien..
AQ
01/07BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patien..
AQ
23/06BioCryst Announces ORLADEYO (berotralstat) Data to be Presented at European Academy of ..
AQ
22/06BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of..
AQ
10/06BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO (berotralstat) in Latin..
AQ
09/06BioCryst Pharmaceuticals, Inc. - FDA Grants Fast Track Designation for BioCryst's ALK-2..
AQ
09/06BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Lati..
AQ
08/06BioCryst Announces Approval of ORLADEYO (berotralstat) by Swissmedic
AQ
08/06FDA Grants Fast Track Designation for BioCryst's ALK-2 Inhibitor, BCX9250
AQ
07/06Biocryst Pharmaceuticals Inc : Change in Directors or Principal Officers, Submission of Ma..
AQ
07/06BioCryst Announces Approval of ORLADEYO® (berotralstat) by Swissmedic
AQ
07/06BioCryst Announces Health Canada has Authorized ORLADEYO (berotralstat), the Only Oral ..
AQ
06/06BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral..
AQ
01/06BioCryst to Present at Upcoming Investor Conferences
AQ
09/05BioCryst to Present at Upcoming Investor Conferences
AQ
09/05BIOCRYST PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Conditi..
AQ
06/05BioCryst to Present at Upcoming Investor Conferences
AQ
05/05BioCryst Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
05/05Biocryst : Q1 Earnings Snapshot
AQ
05/05Biocryst Pharmaceuticals Inc : Results of Operations and Financial Condition, Regulation F..
AQ
05/05BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones
AQ
04/05BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
28/04European Medicines Agency Grants PRIME Designation to BioCryst's ALK-2 Inhibitor, BCX92..
AQ
27/04European Medicines Agency Grants PRIME Designation to BioCryst's ALK-2 Inhibitor, BCX92..
AQ
21/04BioCryst to Report First Quarter 2022 Financial Results on May 5
AQ
11/04BioCryst to Present at Upcoming Investor Conference
AQ
11/04Biocryst Pharmaceuticals : Regulation FD Disclosure - Form 8-K
PU
11/04Biocryst Pharmaceuticals Inc : Regulation FD Disclosure (form 8-K)
AQ
08/04Biocryst Pharmaceuticals : Pauses Enrollment in BCX9930 Clinical Trials - Form 8-K
PU
08/04Biocryst Pharmaceuticals Inc : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/04BioCryst Pauses Enrollment in BCX9930 Clinical Trials
AQ
05/04BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
03/03BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
03/03BioCryst to Present at Upcoming Investor Conferences
AQ
02/03BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
01/03BIOCRYST PHARMACEUTICALS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
25/02BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Impro..
AQ
24/02BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Impro..
AQ
23/02Biocryst : Q4 Earnings Snapshot
AQ
23/02Biocryst Pharmaceuticals : Reports Fourth Quarter and Full Year 2021 Financial Results and..
PU
23/02Biocryst Pharmaceuticals Inc : Results of Operations and Financial Condition, Regulation F..
AQ
23/02BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key M..
AQ
22/02Biocryst Pharmaceuticals : Begins Patient Enrollment in RENEW Proof-of-Concept Trial Evalu..
PU
22/02Biocryst Pharmaceuticals Inc : Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
22/02BioCryst Begins Patient Enrollment in RENEW Proof-of-Concept Trial Evaluating BCX9930 f..
AQ
17/02Biocryst Pharmaceuticals Inc : Regulation FD Disclosure (form 8-K)
AQ
09/02BioCryst to Report Fourth Quarter 2021 Financial Results on February 23
AQ
08/02Biocryst Pharmaceuticals : Appoints Machelle Sanders to Board of Directors - Form 8-K
PU
08/02Biocryst Pharmaceuticals Inc : Change in Directors or Principal Officers, Financial Statem..
AQ
08/02BioCryst Appoints Machelle Sanders to Board of Directors
AQ
1  2  3  4  5  6  7  8  9  10Volgende
Volgende evenement op BIOCRYST PHARMACEUTICALS, INC.